Aktuellt
SENASTE
Redeye comments on FDA granting Fast Track Designation for arfolitixorin in metastatic colorectal cancer. The news reinforces our conviction in our estimated timeline, with a projected arfolitixorin US launch as soon as mid-2023. We judge todays’ news could improve sentiment around Isofol’s share, though we still see AGENT top-line data as the primary determinant for the company’s future.
LÄS MER
